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Abstract
Summary The appropriate time to initiate bisphosphonate
treatment after a fragility fracture has not yet been established.
In this study, we found no significant differences in short-term
functional recovery between femoral neck fracture patients
who received bisphosphonate treatment at 2 versus 12 weeks
after hemiarthroplasty.
Introduction Bisphosphonate is the mainstay therapy for pre-
vention and treatment of osteoporosis. The aim of this study
was to investigate the effect of bisphosphonate initiation on
short-term functional recovery in femoral neck fracture pa-
tients at 2 versus 12 weeks after hemiarthroplasty.
Methods One hundred patients were randomly allocated into
two groups in a parallel group designed, randomized, controlled
trial. Both groups received risedronate 35 mg/week at either 2
or 12 weeks after hemiarthroplasty. All patients received calci-
um and vitamin D supplementation. Functional recovery was
assessed by de MortonMobility Index, Barthel Index, EuroQol
5D, visual analog scale, 2-min walk test, and timed get-up-and-
go test at 2 weeks, 3 months, and 1 year after surgery.
Results At the 3-month follow-up, all functional outcome
measures showed significant improvement in both groups.
There were no statistically significant differences in any of
the functional outcomes between groups at both the 3-month
and 1-year follow-ups. Although patients who received bis-
phosphonate initiation at week 2 had lower serum calcium
level at 3 months and more overall adverse events than pa-
tients in the week 12 group, no patients in either group
discontinued their prescribed medications.
Conclusions While underpowered, the findings of this study
suggest that there were no significant differences in short-term
functional recovery or significant adverse events between the
two bisphosphonate groups. Thus, the initiation of bisphos-
phonate therapy may be considered as early as 2 weeks after
femoral neck fracture. It is important that low serum calcium
and vitamin D status must be corrected with calcium and
vitamin D supplementation prior to or at the time of bisphos-
phonate initiation.
Clinical trial registration number This study was registered
in the database via the Protocol Registration and Results
System (PRS) (NCT02148848).
Keywords Randomized controlled trial . Femoral neck
fracture . Bisphosphonate . Risedronate . Hemiarthroplasty
Introduction
Hip fracture is a common osteoporotic fracture among the
elderly and is a major public health concern worldwide [1].
It was estimated that the total number of hip fractures in per-
sons 50 years of age or older will increase worldwide from 1.7
million in 1990 to 6.3 million in 2050 [2]. With changes in the
demographics of populations around the world and more el-
derly living in developing countries, it is predicted that half of
all hip fractures will occur in Asia [3]. Hip fracture among the
elderly results in serious health consequences with significant
mortality and significant loss of mobility and independence
among those who survive [4, 5]. It was reported that only
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about 40% of hip fracture patients could return to their
preinjury level of walking [6]. In addition, the risk of subse-
quent hip fracture increases dramatically in this population.
Patients with history of fracture have an 86% increase in the
risk of sustaining another fracture [7], and half of hip fracture
patients have suffered prior fragility fractures [8].
Furthermore, the cost of treating a hip fracture patient is high,
with costs being approximately three times higher than those
incurred when caring for a patient without a fracture [9, 10]. It
is, therefore, essential to develop an effective prevention pro-
gram and to initiate osteoporosis treatment in these patients to
prevent or minimize the chance of future fracture. Although
many strategies have been implemented to manage osteopo-
rosis patients, the rate of osteoporosis evaluation and treat-
ment remains low [11]. This may suggest that some physi-
cians had insufficient participation in the prevention of their
patients’ secondary fracture. If an intervention with good effi-
cacy can be implemented soon after a fragility fracture has
been diagnosed, it is plausible to assume that the rate of oste-
oporosis treatment will increase.
Among all osteoporosis drugs, bisphosphonates are the
most commonly prescribed medicat ion [12]. Bis
phosphonates are structurally related to pyrophosphates,
which are incorporated into the bone matrix by binding to
calcium and hydroxyapatite [13]. Once administered,
bisphosphonates inhibit bone resorption by blocking farnesyl
diphosphate synthase in the mevalonate pathway, which, in
turn, leads to osteoclast apoptosis [14]. Studies have shown
that bisphosphonates reduce the incidence of vertebral and
nonvertebral fractures (including hip fractures) when used to
treat postmenopausal osteoporosis [15].
Hemiarthroplasty is a common surgical procedure for treat-
ment of displaced femoral neck fracture in the elderly [16],
because it provides stable fixation and allows for early mobi-
lization of the patient. Femoral neck fracture patients that are
treated with arthroplasty provide a good opportunity for or-
thopedic surgeons to initiate osteoporosis treatment, because
there is no concern regarding fracture healing in these patients.
However, some physicians have expressed concern regarding
the initiation of bisphosphonate prior to correcting low calci-
um and vitamin D status—a condition that is very common in
hip fracture patients [17]. Maalouf et al. [18] reported three
cases of bisphosphonate-induced hypocalcemia and conclud-
ed that this type of hypocalcemia could develop in patients
with unrecognized hypoparathyroidism, impaired renal func-
tion, and vitamin D deficiency. We hypothesized that early
initiation of bisphosphonate treatment would not affect post-
operative functional outcomes and would not increase the rate
of adverse effect of bisphosphonate in this group of patients.
Accordingly, the objective of this randomized controlled study
was to investigate the effect of bisphosphonate initiation on
short-term functional recovery in femoral neck fracture pa-
tients at 2 versus 12 weeks after hemiarthroplasty.
Methods
The protocol and consent forms used in this studywere approved
by the Siriraj Institutional Review Board (SIRB), Faculty of
Medicine Siriraj Hospital, Mahidol University. This study was
registered in the ClinicalTrials.gov database via the Protocol
Registration and Results System (PRS) (NCT02148848). A
detailed informed consent formwas signed by each participating
patient, and all patient information was kept confidential. The
study design and reporting format were based on Consolidated
Standards of Reporting Trials (CONSORT) principles.
We prospectively screened patients within 2 weeks after
surgery who underwent hemiarthroplasty for femoral neck frac-
ture at Siriraj Hospital during the June 2013 to June 2015 study
period. Siriraj Hospital is Thailand’s largest university-based
national tertiary referral center. Exclusion criteria were as fol-
lows: pathologic fracture; multiple fractures; patients with histo-
ry of abnormalities of the esophagus that delay esophageal emp-
tying, such as stricture or achalasia; patients who were unable to
remain upright for 30 min after dosing; patients with hypocalce-
mia (serum calcium <8.5 mg/dL), severe vitamin D deficiency
(serum 25-hydroxyvitamin D (25(OH)D) <10 ng/mL), or meta-
bolic bone diseases other than postmenopausal osteoporosis; pa-
tients with estimated glomerular filtration rate (eGFR) less than
35 mL/min/1.73 m2 (eGFR was calculated by using the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) equa-
tion); patients with postoperative complications that required
modification of the postoperative rehabilitation protocol; and
patients with severe cognitive impairment. Patients were also
excluded if they had taken estrogen (or its analogs) or anabolic
steroids within the preceding 6months. Prior use of any bisphos-
phonate or anabolic agent within 1 year of the study or for
≥2 years within any 5-year period was also a reason for exclu-
sion. Lastly, any patient who was treated with glucocorticoids
(≥5 mg/day of prednisolone or its equivalent) within the past
6 months was also not approved for participation in this study.
Patients who met all eligibility criteria were enrolled and
sequentially assigned an allocation number into one of the two
groups. Randomization was stratified by mode of fixation
(cemented or cementless) to balance potential prognostic
characteristics between groups. The randomization sequence
was concealed prior to enrollment. Although patients and phy-
sicians were not blinded to the given intervention, the research
assistant who collected the study data was blinded to which
treatment arm the patient had been assigned. Patients were allo-
cated to starting bisphosphonate at either week 2 or week 12
postoperatively by a computer-generated blocked randomization
scheme using block sizes of 2 and 4. Block randomization was
performed according to the type of treatment. Participants were
randomized according to the study protocol, with 49 patients
allocated to the bisphosphonate initiation at week 2 group and
51 patients allocated to the bisphosphonate initiation at week 12
group. Patients in the bisphosphonate initiation at week 2 group
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received risedronate (Actonel; Procter & Gamble
Pharmaceuticals, Cincinnati, OH, USA) 35mg/week at 2 weeks
after surgery. Patients in the bisphosphonate initiation at week
12 group received risedronate 35 mg/week at 12 weeks postop-
eratively. For ethical reasons, bisphosphonates were deferred for
no longer than 3months in the bisphosphonate initiation at week
12 group. Risedronate was taken with a full glass of water
(6–8 oz) after fasting and upon arising in the morning. The
patient was asked to remain in an upright position for approxi-
mately 30 min before taking first food or beverage of the day. In
addition to the study medication, all patients were instructed to
take calcium (1000 mg/day) and vitamin D supplementation.
Vitamin D supplementation was given according to the patient’s
baseline serum 25(OH)D level. Patients received vitamin D2
dosages, as follows: Those with a 25(OH)D level of 30–
40 ng/mL received 20,000 IU of vitamin D2 per week; those
with a 25(OH)D level of 20–30 ng/mL received 40,000 IU per
week; and those with a 25(OH)D level of <20 ng/mL received
60,000 IU per week. Patients who had a 25(OH)D level of
>40 ng/mL were not given additional vitamin D2 supplementa-
tion. At the conclusion of the study, participants were advised to
continue calcium and vitamin D supplementation indefinitely,
and that anti-osteoporosis therapies should be considered or
continued at their physician’s discretion.
Surgery and postoperative rehabilitation protocol
All operations were performed via a posterior approach. The
prostheses used in this study were either cementless,
metaphyseal fit stem-type, or cemented, polished-type femoral
component. Decision regarding type of fixation was based on
intraoperative stability of the implant. Adequacy of stability for
cementless implant was evaluated and determined from stabil-
ity status in three dimensions: axial, rotation, and flexion exten-
sion. If adequate stability of a cementless implant could not be
achieved during surgery, a cemented stem would then be im-
planted. All patients in both groups were treated using the same
postoperative protocol. Physical therapy was started 1 day after
the procedure. The physical therapy protocol consisted of early
mobilization, including bed exercises and training for ambula-
tion. Bed exercises focused on breathing and the postural lower
limbs and were performed using both legs. Exercises included
ankle pumps and buttock contractions. Ambulation training
was divided into the following rehabilitation milestones: (1)
transferring unassisted in and out of bed and (2) being able to
stand and walk with an assisting device on a level surface.
Patients were allowed to bear full weight, regardless of whether
they underwent cemented or cementless fixation. Once they
had achieved their physical therapy goals, patients were
discharged from the hospital to their home or a rehabilitation
facility. It should be noted that the physical therapy goals were
adjusted to the needs of each patient based on his/her
preoperative ambulatory status and household environment.
Physical therapy was given during the hospital admission.
Each patient participated in a 1-h physical therapy session each
weekday on the patient’s hospital unit that consisted of exercise
training and practice. After discharge from the hospital, patients
were instructed to continue exercising by walking on a level
surface. Pain medications included acetaminophen, short-
acting opioids, and intravenous opioids (only during hospital
admission). The goal was to keep pain at no higher than 2 to 3
of 10, as measured by visual analog scale.
Assessment of outcomes
Functional recovery was assessed by deMortonMobility Index
(DEMMI), Barthel Index, EuroQol 5D (EQ-5D), visual analog
scale, 2-min walk test, and timed get-up-and-go test. All of
these functional outcomes were tested at three intervals for
purposes of comparison at the following time points: 2 weeks
(as baseline data), 3 months, and 1 year after surgery. We used
the change in the DEMMI score between baseline and the
3-month follow-up as the primary outcome, with changes in
other scales regarded as being secondary outcomes.
de Morton Mobility Index
DEMMI is a method to evaluate level of patient mobility [19].
DEMMI was validated among patients in rehabilitation fol-
lowing hip fracture and is freely available for download from
www.demmi.org.au [20]. DEMMI is administered to observe
physical performance and consists of 15 hierarchical mobility
items, including three beds, three chairs, four static balance,
two walking, and three dynamic balance items. Each mobility
item is measured on a two (able/unable) or three (able/partial/
unable) point scale [19]. The sum score, ranging from 0 to 58,
is then converted to an interval score that ranges from 0 to 100,
where 0 represents no or very poor mobility and 100 indicates
high levels of independent mobility [20].
Barthel Index
The Barthel Index is an ordinal scale for the functional assess-
ment of disability that has been widely used in individuals re-
ceiving in-patient rehabilitation, mainly in stroke outcome re-
search [21–23]. It has also been used in and validated for hip
fractures in the elderly population [24]. Barthel Index comprises
ten variables that describe activities of daily living (ADLs) and
mobility, including the presence or absence of fecal and/or uri-
nary incontinence, help needed with grooming, toilet use, feed-
ing, transfers, walking, dressing, climbing stairs, and bathing.
Each performance item is rated on a scale with a given number
of points assigned to each level or ranking. A higher score is
associated with a greater likelihood of being able to live at home
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with a degree of independence following discharge from the
hospital [21]. Barthel Index has high inter-rater reliability (0.95)
and test-retest reliability (0.89), as well as high correlations
(0.74–0.8) with other measures of physical disability [25].
EQ-5D
The EQ-5D was designed for self-completion by the partici-
pant. This clinical tool is composed of two parts: the EQ-5D-
5L utility score (EQ-US) and the EQ visual analog scale (EQ-
VAS). In this study, we used only the EQ-VAS, which is a self-
evaluated scale. Patients were asked to score their health status
on a visual analog scale that ranged from 0 to 100. The top
score of the scale (100) represents the best imaginable health
state, while the bottom (0) represents the worst imaginable
state. EuroQol is a reliable and valid instrument for assessing
health-related quality of life in elderly patients with femoral
neck fracture [26].
Visual analog scale
Overall pain was evaluated using visual analog scale. Patients
were asked to rate their pain during the past 24 h on a visual
analog scale that ranged from 0 to 10, with a higher score
reflecting a higher level of pain.
Two-minute walk test and timed get-up-and-go test
Functional evaluation was conducted using two performance-
based tests: 2-min walk test and timed get-up-and-go test. The
results of these two tests were recorded at baseline and at two
postoperative follow-ups by one of our research assistants
who was blinded to the treatment group. For the 2-min walk
test, patients were asked to walk up and down a designated
corridor for 2 min. Patients were instructed to walk at their
normal pace and to turn around at the ends of the corridor
without stopping [27]. Results were recorded as total distance
walked in meters.
For the timed get-up-and-go test, patients were instructed
to rise from a high-seated chair, walk at a safe and comfortable
pace to a mark 3 m away, and return to a sitting position with
their backs against the chair [28]. Patients were permitted to
use their arms when rising from and returning to a seated
position. A stopwatch was used to measure the time to com-
plete this activity to the nearest one tenth of a second. Patients
were asked to perform this task three times, and the average
time was used for analysis.
Statistical analysis
Statistical power was determined from our primary outcome,
which was change in DEMMI score between baseline and the
3-month follow-up. A previous investigation by de Morton
et al. [20] found that the standard deviation of the DEMMI
score in hip fracture patients was 8.9. Based on the results of
that study, we designed the current study to determine a six-
point difference, which is the minimally clinically important
difference in DEMMI score [20] between the two groups, with
a standard deviation of 8.9. Power analysis and sample size
calculations indicated that a sample size of 39 patients per
group would provide 80% statistical power to detect this effect
size between the two groups (alpha = 0.05, beta = 0.20) using
Student’s t test. Since recruitment was increased by 10% to
allow for loss to follow-up, a total of 43 patients per group
were required for this study.
Baseline characteristics and the results of both groups were
compared using Pearson’s chi-squared or Fisher’s exact test
for categorical variables and Student’s t test for continuous
variables. Kolmogorov-Smirnov test was used to test normal-
ity of distribution. One-way repeated measures ANOVAwas
used to assess the effect of time on the change in each outcome
measure for each patient group. Data are presented as number,
number (%), or mean ± standard deviation. An intention-to-
treat analysis was conducted based on the two initial random-
ization groups. All analyses were performed using PASW
Statistics for Windows, version 18.0 (SPSS, Inc., Chicago,
IL, USA). A p value <0.05 was regarded as being statistically
significant.
Results
A total of 133 patients were screened for eligibility during the
study period. Thirty three of those patients were excluded, as
follows: six patients for declining to participate in the study,
six patients who had severe cognitive impairment, eight pa-
tients with eGFR less than 35 mL/min/1.73 m2, four patients
with pathologic fracture, one patient with multiple fractures,
four patients who had history of taking anti-osteoporotic drugs
during the past 1 year, one patient who was unable to remain
upright for 30 min, and three patients with postoperative com-
plications that required modification of the postoperative re-
habilitation protocol (one with a postoperative periprosthetic
femoral fracture and two with active medical conditions). The
remaining 100 patients were enrolled in the study. Participants
were randomized according to the study protocol, with 49
patients being allocated to the bisphosphonate initiation at
week 2 group and 51 patients allocated to the bisphosphonate
initiation at week 12 group. One patient in the week 2 group
died at 9 months after surgery due to an active lung infection.
A total of 15 patients were lost during the follow-up period,
with 6 and 9 of those patients belonging to the week 2 and
week 12 groups, respectively. Three patients discontinued
medication after the randomization process due to their active
medical condition (one and two patients in the week 2 and
 27 Page 4 of 11 Arch Osteoporos  (2017) 12:27 
week 12 groups, respectively). Ninety patients (90%) and 81
patients (81%) completed the study with data available for
analysis at 3 months and 1 year, respectively (Fig. 1).
Demographic and baseline characteristics of each treatment
group are provided in Table 1. Mean age in our study was
76.6 years, and most (80%) subjects were women. A majority
of study participants received bipolar hemiarthroplasty using
cementless femoral component. Approximately 73% of pa-
tients could walk without the use of any assisting device be-
fore fracture. The average length of stay was similar between
the week 2 and week 12 groups (p = 0.534). When comparing
data between the two groups, there were no differences in any
demographic or clinical characteristics, including baseline se-
rum calcium, serum 25(OH)D, and bone mineral density
(p > 0.05 for all comparisons) (Table 1). When comparing
data between patients who completed and did not complete
the study at 1 year, there were no significant differences in
demographic and clinical characteristics between patients
available for analysis and those who did not complete the
study at 1 year, except that there were less female patients in
the group that did not complete the study at 1 year (p = 0.021,
electronic supplementary file table).
At the 3-month postoperative follow-up, functional out-
come in both groups improved significantly (Table 2). The
Fig. 1 Consolidated Standards of
Reporting Trials (CONSORT)
diagram showing the flow of
patients in the study. The group
with bisphosphonate initiation at
week 2 received bisphosphonate
at 2 weeks after surgery. The
group with bisphosphonate
initiation at 12 weeks received
bisphosphonate at 12 weeks after
surgery
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change in scores for DEMMI, Barthel Index, EQ-VAS, and
visual analog scale from baseline to 3 months after surgery
was similar between the two treatment groups (p > 0.05). For
the 2-min walk test at the 3-month postoperative follow-up,
patients in both groups could walk approximately 2.3 times
longer than the distance they could walk at 2 weeks after
surgery. For the timed get-up-and-go test at the 3-month post-
operative follow-up, patients in both groups could perform
this test approximately two times faster than the average re-
corded time at 2 weeks after hemiarthroplasty. There were no
significant differences between the week 2 and week 12
groups for either the 2-min walk test or the timed get-up-
and-go test (Table 2).
Serum calcium and vitamin D levels at baseline and at 3, 6,
and 12 months after calcium and vitamin D supplementation
for both groups are shown in Table 3. Serum 25(OH)D in-
creased significantly in both groups after 3 months of vitamin
D supplementation (mean serum 25(OH)D at 3 months post-
operatively = 33.1 and 33.1 ng/mL for the week 2 and week
12 groups, respectively). There was no statistically significant
difference in postoperative 25(OH)D level between groups at
all time points (p = 0.730–0.966). Serum calcium at 3 months
after surgery was higher in the week 12 group (mean serum
calcium at 3 months postoperatively = 9.1 and 9.4 mg/dL for
the week 2 and week 12 groups, respectively; p = 0.008).
However, there were no differences in serum calcium at 6
and 12 months after surgery between the two groups. Two
patients in the week 2 group complained of myalgia, and
one had flu-like symptoms, while no patients in the week 12
group reported these symptoms (Table 4). The overall rate of
adverse events was higher in the week 2 group than in the
week 12 group, but the difference was not statistically signif-
icant (16.3 vs. 5.9%, respectively; p = 0.095) (Table 4). No
patients in either group discontinued any study medications or
supplements due to these adverse reactions.
When evaluating functional outcomes at 1 year postopera-
tively, we found that all functional outcomes in the week 12
group improved significantly from those recorded at the 3-
month postoperative follow-up (p < 0.007). In the week 2
group, only DEMMI, Barthel Index, and the 2-min walk test
improved significantly from scores recorded at the 3-month
postoperative follow-up (Fig. 2). There were no statistically
significant differences in the improvement of functional out-
comes between groups at both the 3-month and 1-year post-
operative follow-ups (Fig. 2). The percentage of patients who
used gait assisting device increased significantly from 27%
before fracture to 60.5% at 1 year after surgery.
Discussion
Some studies have reported that 45% or more of hip fracture
patients have a prior history of fracture [8, 29], and data indi-
cate that almost half of all women and one third of men with a
Table 1 Patient demographic
and clinical characteristics Clinical variables BIS initiation at
week 2 (n = 49)
BIS initiation
at week 12 (n = 51)
p value
Age (years) 77.3 ± 8.1 75.8 ± 8.3 0.381
Female gender 39 (79.6%) 41 (80.4%) 0.920
Right side 19 (38.8%) 27 (52.9%) 0.155





















Length of hospital stay (days) 12.7 ± 7.7 10.9 ± 4.8 0.534
Estimated glomerular filtration rate (mL/min/1.73 m2) 72.7 ± 20.3 70.2 ± 20.8 0.461
Serum calcium level (mg/dL) 9.0 ± 0.5 9.0 ± 0.6 0.925
Serum 25(OH)D level (ng/mL) 22.8 ± 11.4 21.7 ± 10.3 0.699













Data presented as number (%) or mean ± standard deviation. p value <0.05 indicates statistical significance.
Estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation
BIS bisphosphonate, 25(OH)D 25-hydroxyvitamin D
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hip fracture will suffer a new fragility fracture during their
remaining lifetime [30, 31]. Accordingly, this patient popula-
tion is a target group for osteoporosis intervention to reduce
future fracture risk. It is generally accepted that bisphospho-
nate is the mainstay therapy for prevention and treatment of
osteoporosis. However, when to start bisphosphonate
Table 2 Changes in outcome
































































































Data presented as mean ± standard deviation; p value <0.05 indicates statistical significance
BIS bisphosphonate
Table 3 Changes in serum
calcium and serum vitamin D
levels after calcium and vitamin D
supplementation
Laboratory test BIS initiation
at week 2 (n = 41)
BIS initiation




































Data presented as mean ± standard deviation. p value <0.05 indicates statistical significance
BIS bisphosphonate
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treatment after a fragility fracture has not yet been definitively
established.
Physicians have to consider two major issues before pre-
scribing bisphosphonate after fracture fixation. The first issue
centers on the effect that bisphosphonate will have on fracture
healing. Fracture healing is a complex event that involves
coordination of a variety of different processes, including in-
flammation, soft callus formation, hard callus formation, and
Table 4 Type and frequency of
adverse events among the study
population
Adverse events BIS initiation
at week 2 (n = 49)
BIS initiation
at week 12 (n = 51)
p value




Flu-like symptoms 1 –
Muscle cramp – 1
Hearing impairment 1 –
Deep vein thrombosis 1 –
Ischemic stroke 1 –
Total number of adverse events 8 (16.3%) 3 (5.9%)
Data presented as number or number (%); p value <0.05 indicates statistical significance
BIS bisphosphonate
Fig. 2 Mean change in scores from baseline to 12 months after surgery. a
de Morton Mobility Index. b Barthel Index. c EuroQol visual analog
scale. d Visual analog scale. e Two-minute walk test. f Timed get-up-
and-go test. The error bars indicate the standard error. The p values at
the top of each graph indicate the significance level of each functional
outcome in the bisphosphonate initiation at week 2 group between the
indicated time points. The p values at the bottom of each graph indicate
the significance level of each functional outcome in the bisphosphonate
initiation at week 12 group between the indicated time points
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remodeling and modeling [32]. Once administered,
bisphosphonates bind to hydroxyapatite crystals and inhibit
crystal breakdown [15]. They are preferentially incorporated
into sites with active bone remodeling, and they increase ap-
optosis of osteoclasts, leading to diminished bone resorption.
Since osteoclasts are essential for the callus remodeling pro-
cess, it is hypothesized that bisphosphonate may adversely
affect fracture healing. Xue et al. [33] conducted a systematic
review in bisphosphonates and their influence on fracture
healing and found that bisphosphonates significantly
prolonged healing times in patients with distal radius frac-
tures, but not in patients with femoral fractures. As a result
of this prevailing concern regarding the effect of bisphospho-
nate on fracture healing, most orthopedic surgeons delay the
initiation of bisphosphonate therapy for a few months after
fracture fixation. The second issue relates to the potential in-
duction of symptomatic hypocalcemia if bisphosphonate is
given to those with pre-existing low serum calcium and vita-
min D level [18]. For this reason, some physicians prefer to
delay bisphosphonate treatment for a few months after frac-
ture repair. In this study, we postponed bisphosphonate treat-
ment for 3 months after fracture treatment due to the result
reported from a previous investigation, which showed a 28%
reduction in overall mortality in patients who received intra-
venous bisphosphonate within 90 days after surgical repair of
an osteoporotic hip fracture [34]. Determining whether a lon-
ger delay in bisphosphonate treatment adversely affects func-
tional recovery after hemiarthroplasty in femoral neck fracture
patients would require a longer period of no bisphosphonate
treatment, which could have ethical implications relative to
what is considered safe and unsafe patient care.
Although guideline-recommended osteoporosis treatment
with bisphosphonate can substantially reduce fracture risk to
approximately 30–40% [35–37], the rate of osteoporosis treat-
ment following hip fracture remains low [38–40]. One inter-
vention that may improve osteoporosis treatment rates is the
establishment of a fracture liaison service [41]. Another pos-
sible intervention is to encouraging physicians and orthopedic
traumatologists to initiate osteoporosis treatment soon after
fracture repair. Because the present study found no differences
in short-term functional outcomes or significant adverse
events between groups, early bisphosphonate treatment at
2 weeks after fracture fixation might be beneficial in hip frac-
ture patients for several reasons. First, starting bisphosphonate
therapy early would prevent a delay in osteoporosis treatment.
Second, data from a large fracture trial showed that bisphos-
phonate treatment reduced fracture risk as early as 6 months
after treatment initiation [42, 43]. Given that a majority of hip
fracture patients are still in the hospital at the 2-week time
point after fracture fixation, early bisphosphonate initiation
would facilitate a closely monitored, medically supervised
start to long-term osteoporosis treatment, which may improve
the effectiveness of a posthip fracture care program.
It is important to emphasize that low calcium and vitamin
D status must be corrected before or during the initiation of
anti-osteoporosis therapy. This correction will reduce the risk
of hypocalcemia and worsening secondary hyperparathyroid-
ism that might occur if the patients are not rendered vitamin D
replete prior to bisphosphonate treatment [44]. Furthermore,
correction of hypovitaminosis D and hypocalcemia might en-
hance the response of bisphosphonate treatment [45]. Our
results showedmean serum calcium level at the 3-month post-
operative follow-up in the bisphosphonate initiation at week 2
group to be significantly lower than that of the week 12 group
(9.1 vs. 9.4 mg/dL; p = 0.008). In addition, the rate of total
adverse events in the week 2 group (16.3%) was higher than
that of the week 12 group (5.9%). These findings can be ex-
plained by the action of the bisphosphonate in the week 2
group. Bisphosphonates are potent inhibitors of osteoclastic
bone resorption. This inhibition decreases calcium efflux from
bone, leading to a transient period of slight hypocalcemia.
Most patients, however, do not become hypocalcemic due to
compensatory mechanisms, the most important of which is
increased secretion of parathyroid hormone [46]. In this study,
we gave calcium and vitamin D supplementation to all pa-
tients within 2 weeks in both groups and none of them devel-
oped symptomatic hypocalcemia or discontinued the medica-
tions due to any adverse reactions. We, therefore, recommend
that treating physicians correct low calcium and vitamin D
levels together with the initiation of any osteoporosis drugs
in order to reduce the potential side effects of osteoporotic
medications.
This study has several mentionable limitations. First, the
patients and physicians were not blinded, because a placebo
pill was not used. Although this is a potential source of bias,
our research assistants (who were unaware of the group allo-
cations) administered the questionnaires and performed the
functional outcome assessments. Second, patients in our study
with no history of bisphosphonate therapy received only one
type of bisphosphonate (risedronate). We are, therefore, un-
able to address whether patients who had prior history of bis-
phosphonate treatment and those who took other types of
bisphosphonate would have had similar results. In addition,
our findings cannot be directly extrapolated to hip fracture
patients who received non-operative treatment and those with-
out hip fracture. Third, our sample size was calculated to de-
termine a six-point difference in DEMMI score between
groups. Thus, our sample size was too small to detect other
clinically important secondary outcome measures, such as vi-
sual analog scale, 2-min walk test, and adverse reactions.
Furthermore, the 18.9 standard deviation of the DEMMI score
found in our study at the 3-month follow-up was much higher
than the 8.9 standard deviation reported in a previous investi-
gation [20]. As previously described, a standard deviation of
8.9 was used to calculate the sample size for this study. When
we used our standard deviation of 18.9 to calculate the power
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of the study, we found the power to be only 46. Caution
should, therefore, be exercised when interpreting our results.
At a standard deviation of 18.9, each group would have to
have included 117 patients to achieve a power of 80. This
information was not available until after the study was com-
pleted. Hence, this research should be regarded as a prelimi-
nary study that investigated the effect of bisphosphonate ini-
tiation at week 2 versus week 12 on short-term functional
recovery in patients with a femoral neck fracture. Finally, the
duration of follow-up in this study was relatively short.
However, longer term follow-up is difficult due to a short life
expectancy in this patient population [47].
In conclusion, no significant differences in short-term func-
tional recovery or significant adverse events were observed
between the week 2 and week 12 bisphosphonate initiation
groups. As such, initiation of bisphosphonate therapy may be
considered as early as 2 weeks after femoral neck fracture. It is
important to emphasize that low serum calcium and vitamin D
status must be corrected with calcium and vitamin D supple-
mentation prior to or at the time of bisphosphonate initiation.
Further studies in a larger population are needed to confirm
the results of our study.
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